Abstract: The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody “trastuzumab” (HERCEPTIN®) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody “matuzumab” (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer.
Type:
Grant
Filed:
November 10, 2014
Date of Patent:
December 20, 2016
Assignee:
L'Institut National de la Sante et de la Recherche Medicale
Inventors:
Stephen D. Gillies, David Azria, Christel Larbouret, André Pelegrin
Abstract: A cell separation process for the isolation of pathogenic cells in a small concentration in a biological fluid specimen, including treating the biological specimen to modify in a differential manner selected rare cells and other cells and causing differential migration of cells that reacted during treatment versus cells that did not react during treatment.
Type:
Grant
Filed:
February 22, 2001
Date of Patent:
January 8, 2008
Assignees:
L'Institut National de la Sante et de la Recherche Medicale (INSERM), L'Assistance Publique, Hopitaux de Paris (AP-HP), L'Universite Rene Descartes Paris 5
Inventors:
Jean-Claude Bisconte de Saint Julien, Patricia Paterlini